Novartis UK today announced that it will initiate consultation on proposals to close its Horsham site in West Sussex. These proposals will impact up to 371 roles, but will be subject to an employee consultation process and final UK board approval.
The company will work with everyone affected, including associates, contractors, suppliers and local stakeholder groups, to make the process as straightforward and smooth as possible.
This potential restructure of operations at the Horsham site is the result of a global review of research operations and realignment of the company’s other global R&D sites. The proposals are part of the company’s ongoing efforts to align resources to better serve patients and customers in a challenging healthcare marketplace.
Separately, the UK pharmaceuticals division based at Frimley, Surrey, will also be announcing the proposed withdrawal of marketing and sales support for our products in diabetes and chronic obstructive pulmonary disease (COPD) in the UK. All these products will still be available to customers and patients in the UK with no change in supply or accessibility at this time. This may impact 72 associates, most of whom are field based.
These changes will not affect the rest of Novartis current UK business in developing, manufacturing and marketing prescription and over-the-counter medicines, vaccines and eye care products for patients who need them, as well as animal health products.
Date: November 5, 2013
Source: Novartis UK
Filed Under: Drug Discovery